Stock ONCY ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Oncolytics Biotech Inc. Nasdaq

Equities

ONCY

CA6823108759

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-07-02 EDT 		5-day change 1st Jan Change
0.99 USD -0.52% Intraday chart for Oncolytics Biotech Inc. -1.98% -26.67%
06-27 Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program MT
06-27 Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program MT

Evolution of the average Target Price on Oncolytics Biotech Inc.

Price target over the last 5 years

History of analyst recommendation changes

57b5d6f31981f5ef6.cJJvVA7ici6kGaA0rwDF6LBQnkYYWf97CNA6gglJ9VY.EtweB0yUPB3PSOFlm2Sij-U00C1aIZ5MO4FLwEYjwx5G0CoMSIcGfcVAmA~41acd5b23f45440bb95f105714ff721a

Analyst Recommendations on Oncolytics Biotech Inc.

RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA MT
HC Wainwright Adjusts Price Target on Oncolytics Biotech to $5 From $15, Maintains Buy Rating MT
JonesTrading Initiates Oncolytics Biotech at Buy With $9 Price Target MT
Canaccord Genuity Adjusts Price Target on Oncolytics Biotech to $5 From $6, Maintains Buy Rating MT
Maxim Initiates Oncolytics Biotech With Buy Rating, Sets Price Target at $3 MT
RBC Capital Keeps OutperformSpeculative on Oncolytics Biotech MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk Rating, $6 TP on Oncolytics Biotech MT
ONCOLYTICS BIOTECH : HC Wainwright Starts Oncolytics Biotech at Buy With $15 Price Target MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk on Oncolytics Biotech After Q3 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.37 CAD
Average target price
6.625 CAD
Spread / Average Target
+383.58%
High Price Target
9 CAD
Spread / Highest target
+556.93%
Low Price Target
3 CAD
Spread / Lowest Target
+118.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Oncolytics Biotech Inc.

HC Wainwright
JonesTrading Institutional Services
Canaccord Genuity
Maxim
RBC Capital Markets

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ONC Stock
  4. ONCY Stock
  5. Consensus Oncolytics Biotech Inc.